GLP1 Diabetes Showdown Nears As Lyxumia Gets Green Light In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The EU's Committee for Medicinal Products for Human Use has recommended two Sanofi products - the diabetes therapy Lyxumia and the colorectal cancer drug Zaltrap – while also backing the first vaccine in Europe for meningitis B, Novartis' Bexsero.
You may also be interested in...
Zealand Pharma Lands Novel Eli Lilly R&D Deal In Diabetes And Obesity
Zealand Pharma has landed another major partnership, this time with Lilly to help develop what the Danish biotech hopes will be a novel, best-in-class treatment for obesity and type 2 diabetes. The process will take years but could lead to other innovative drug deals with the U.S. drug maker.
New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP
Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.
Market For Sanofi And Regeneron’s Zaltrap Could Be Limited
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.